Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blue Light vs White Light Resection in High-risk NMIBC
NCT06525571Phase 3Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hexaminolevulinate in bladder cancer (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Residual disease burden at 24 months and Minimal residual disease burden at 24 months. Started Dec 2024; status: recruiting.
02
Drugs
hexaminolevulinate
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06525571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525571.